Reta 15mg

Retatrutide is an experimental once-weekly injectable that is currently undergoing Phase 3 clinical trials. Often referred to as a "triple-G" agonist, it is the first drug of its kind designed to target three distinct hormones that regulate appetite, metabolism, and blood sugar. In lab rats and mice, retatrutide—a novel triple agonist targeting GLP-1, GIP, and glucagon receptors—demonstrates pronounced weight loss, improved glucose homeostasis, and neuroprotective properties. While highly effective for metabolic health,

For research purposes only 

not for human consumption